Completed PHASE1 INTERVENTIONAL 3-arm NCT02527746

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to Chemotherapy in Subjects With Breast Cancer

Sponsor: EVIVE Biotechnology

Conditions Breast Cancer Neutropenia

Interventions EC regimen F-627

Updated 8 times since 2017 Last updated: Jul 18, 2023 Started: Dec 31, 2012 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Breast Cancer and Neutropenia and is currently completed. EVIVE Biotechnology leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2024 — Jul 2024 [monthly]

Completed PHASE1

Phase: PHASE1_PHASE2 → PHASE1
Mar 2022 — Mar 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Mar 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EVIVE Biotechnology
Fudan University

Data source: EVIVE Biotechnology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.